Fabry disease revisited: Management and treatment recommendations for adult patients

Alberto Ortiz, Dominique P. Germain, Robert J. Desnick, Juan Politei, Michael Mauer, Alessandro Burlina, Christine Eng, Robert J. Hopkin, Dawn Laney, Aleš Linhart, Stephen Waldek, Eric Wallace, Frank Weidemann, William R. Wilcox

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the “classic” phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.

Original languageEnglish (US)
Pages (from-to)416-427
Number of pages12
JournalMolecular Genetics and Metabolism
Volume123
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Fabry Disease
Disease Management
Enzyme Replacement Therapy
Pediatrics
Phenotype
Enzymes
Galactosidases
Therapeutics
Glycosphingolipids
Guidelines
Monitoring
Enzyme activity
X Chromosome Inactivation
Chromosomes
Secondary Prevention
Genes
Physicians
Mutation

Keywords

  • Diagnosis
  • Fabry disease
  • Management
  • Mutation
  • Treatment

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't

Cite this

Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., ... Wilcox, W. R. (2018). Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 123(4), 416-427. https://doi.org/10.1016/j.ymgme.2018.02.014

Fabry disease revisited : Management and treatment recommendations for adult patients. / Ortiz, Alberto; Germain, Dominique P.; Desnick, Robert J.; Politei, Juan; Mauer, Michael; Burlina, Alessandro; Eng, Christine; Hopkin, Robert J.; Laney, Dawn; Linhart, Aleš; Waldek, Stephen; Wallace, Eric; Weidemann, Frank; Wilcox, William R.

In: Molecular Genetics and Metabolism, Vol. 123, No. 4, 01.04.2018, p. 416-427.

Research output: Contribution to journalReview article

Ortiz, A, Germain, DP, Desnick, RJ, Politei, J, Mauer, M, Burlina, A, Eng, C, Hopkin, RJ, Laney, D, Linhart, A, Waldek, S, Wallace, E, Weidemann, F & Wilcox, WR 2018, 'Fabry disease revisited: Management and treatment recommendations for adult patients' Molecular Genetics and Metabolism, vol. 123, no. 4, pp. 416-427. https://doi.org/10.1016/j.ymgme.2018.02.014
Ortiz, Alberto ; Germain, Dominique P. ; Desnick, Robert J. ; Politei, Juan ; Mauer, Michael ; Burlina, Alessandro ; Eng, Christine ; Hopkin, Robert J. ; Laney, Dawn ; Linhart, Aleš ; Waldek, Stephen ; Wallace, Eric ; Weidemann, Frank ; Wilcox, William R. / Fabry disease revisited : Management and treatment recommendations for adult patients. In: Molecular Genetics and Metabolism. 2018 ; Vol. 123, No. 4. pp. 416-427.
@article{d10183ce1c2e4033ae7598058924bea6,
title = "Fabry disease revisited: Management and treatment recommendations for adult patients",
abstract = "Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the “classic” phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.",
keywords = "Diagnosis, Fabry disease, Management, Mutation, Treatment",
author = "Alberto Ortiz and Germain, {Dominique P.} and Desnick, {Robert J.} and Juan Politei and Michael Mauer and Alessandro Burlina and Christine Eng and Hopkin, {Robert J.} and Dawn Laney and Aleš Linhart and Stephen Waldek and Eric Wallace and Frank Weidemann and Wilcox, {William R.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.ymgme.2018.02.014",
language = "English (US)",
volume = "123",
pages = "416--427",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Fabry disease revisited

T2 - Management and treatment recommendations for adult patients

AU - Ortiz, Alberto

AU - Germain, Dominique P.

AU - Desnick, Robert J.

AU - Politei, Juan

AU - Mauer, Michael

AU - Burlina, Alessandro

AU - Eng, Christine

AU - Hopkin, Robert J.

AU - Laney, Dawn

AU - Linhart, Aleš

AU - Waldek, Stephen

AU - Wallace, Eric

AU - Weidemann, Frank

AU - Wilcox, William R.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the “classic” phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.

AB - Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the “classic” phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.

KW - Diagnosis

KW - Fabry disease

KW - Management

KW - Mutation

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85043395605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043395605&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2018.02.014

DO - 10.1016/j.ymgme.2018.02.014

M3 - Review article

VL - 123

SP - 416

EP - 427

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 4

ER -